Form 4: Paragon 28 Executive Andrew Hill Reports Acquisition of Restricted Stock Units

EVP of Research & Development at Paragon 28, Andrew James Hill, reports the acquisition of restricted stock units and a decrease in holdings.

Summary

• On March 20, 2025, Andrew James Hill, EVP of Research & Development at Paragon 28, acquired 49,884 restricted stock units (RSUs).
• These RSUs convert to common stock on a 1:1 basis upon vesting.
• 25% of the RSUs will vest annually starting March 20, 2025, contingent upon continued service to the Issuer.
• Following the transaction, Hill beneficially owns 126,397 shares of common stock, including 114,316 RSUs.
• There was also a disposal of shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock transactions by an executive. The acquisition of RSUs is generally positive, but the disposal of shares tempers the overall sentiment.

Positives

• The acquisition of RSUs suggests continued alignment of the executive's interests with the company's long-term performance.

Negatives

• The document indicates a disposal of shares, which could be interpreted negatively by some investors.

Risks

• The vesting of RSUs is contingent upon continued service, creating a potential risk if the executive leaves the company before full vesting.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs implies a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates ongoing equity-based compensation practices at Paragon 28.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company, but the disposal of shares could offset this.

Key Dates

Keywords

Form 4, Paragon 28, FNA, Andrew James Hill, Restricted Stock Units, RSUs, Beneficial Ownership, EVP Research and Development